Machine learning for prediction of chronic kidney disease progression: Validation of the Klinrisk model in the CANVAS Program and CREDENCE trial

Documenti analoghi

• Variability in HbA1c and the risk of major clinical outcomes in type 2 diabetes with chronic kidney disease: Post hoc analysis from the CREDENCE trial
  di: Ying Zhu, et al.
  Pubblicazione: (2025)
• The Efficacy and Safety of Canagliflozin by Frailty Status in Participants of the CANVAS and CREDENCE Trials
  di: Tu N. Nguyen, et al.
  Pubblicazione: (2025)
• An overview of the CANVAS Program and CREDENCE trial: The primary outcomes and key clinical implications for those managing patients with type 2 diabetes
  di: Angela X. Chen, et al.
  Pubblicazione: (2024)
• Prediction of new‐onset heart failure in patients with type 2 diabetes derived from ALTITUDE and CANVAS
  di: Fatema Said, et al.
  Pubblicazione: (2024)
• Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trial
  di: Kathryn Cardoza, et al.
  Pubblicazione: (2024)